The majority of these CVOTs investigated the effect of previous cardiovascular disease on the cardiovascular efficacy of GLP1-RAs using 3-point MACE as a primary outcome, and with heart failure being a common secondary outcome, focusing on relative rather than absolute benefit. This evidence concerns the gene GLP1R and cardiovascular disorder.